About the Company
novel therapeutics for metabolic and endocrine disorders.
Please visit http://www.vikingtherapeutics.com for more information about the company.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $VKTX News
Is It Too Late to Buy Viking Therapeutics Stock?
Viking Therapeutics (NASDAQ: VKTX) has emerged this year as a formidable contender in the increasingly popular anti-obesity ...
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals
That's what has happened this year to Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech, with its stock price up by ...
Buy Rating Affirmed for Viking Therapeutics Amid Promising Obesity Drug Trials and Strategic Market Positioning
Thomas Smith, an analyst from Leerink Partners, assigned the Buy rating on Viking Therapeutics (VKTX – Research Report). The associated ...
Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock’s a buy.
Viking Therapeutics Inc.’s stock rose 1.9% early Wednesday to add to its prior-day gains, as analysts welcomed positive data ...
Behind the Scenes of Viking Therapeutics's Latest Options Trends
An analyst from Oppenheimer has decided to maintain their Outperform rating on Viking Therapeutics, which currently sits at a ...
Viking Therapeutics Stock Soars on Successful Trial
Viking Therapeutics (VKTX) stock is surging after its experimental tablets helped reduce weight in an early-stage trial ...
Viking Therapeutics Jumps on Early Weight-Loss Pill Results
Viking Therapeutics Inc. rose sharply in premarket trading after the startup unveiled results from an early study of its experimental weight-loss pill, a product expected to compete with popular ...
What's Going On With Viking Therapeutics (VKTX) Stock?
Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading lower by 10.9% to $63.95 Monday afternoon, despite a lack of company ...
Viking Therapeutics gains on early data for oral weight loss therapy
Viking Therapeutics (VKTX) stock gained after company posted Phase 1 data for its oral obesity therapy VK2735. Read more here ...
Buy Rating Upheld for Viking Therapeutics as VK2735 Shows Promising Clinical Results in Obesity Management
Naz Rahman, an analyst from Maxim Group, reiterated the Buy rating on Viking Therapeutics (VKTX – Research Report). The associated price ...
Viking Therapeutics Unusual Options Activity For March 19
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical ...
Rx Rundown: Merck, Novo Nordisk, Viking Therapeutics and more
Bristol Myers Squibb is in the process of laying off 252 employees at its Mirati Therapeutics facility in San Diego. Catalent ...
Loading the latest forecasts...